NUFORMIX PLC

Regulatory Filings • May 29, 2025

National Storage Mechanism | Additional information

RNS Number : 5029K

Nuformix PLC

29 May 2025

29 May 2025

Nuformix plc

("Nuformix" or the "Company")

Confirmation of European Orphan Drug Designation for NXP002 Programme in IPF

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce, further to the Company's announcement on 30 April 2025, that the European Medicines Agency ("EMA") has granted Orphan Drug Designation ("ODD") in Idiopathic Pulmonary Fibrosis ("IPF") for tranilast, the active drug substance enabled for inhaled delivery in Nuformix's NXP002 lead programme.

ODD in the European Union ("EU") is granted by the European Commission based on a positive opinion adopted by the EMA Committee for Orphan Medicinal Products that can demonstrate potential for significant advancement in treatment of rare and debilitating diseases affecting no more than five in 10,000 individuals in the EU. ODD provides incentives to developers of medicines for limited patient populations, including 10 years market exclusivity, protocol assistance (guidance on study design and scientific evaluation) and regulatory fee reductions.

Phil Molyneaux, MD, Professor of Pulmonary Medicine at the Royal Brompton Hospital, London, commented: " Patients with IPF currently lack treatment options that significantly alter the course of their disease. They also often face tolerability issues with existing therapies. Inhaled therapies like NXP002 offer the potential for improved efficacy by delivering the drug directly to the lungs, while avoiding the side effects associated with oral treatments. This approach could represent a meaningful step forward in addressing the urgent need for better treatment options for patients with IPF."

Dr Dan Gooding, Executive Director, Nuformix, said: " We are delighted to receive confirmation that Orphan Drug Designation has been granted for our NXP002 programme in IPF. The EMA award recognises NXP002's potential to significantly advance IPF treatment, thanks to its ability to modulate key targets in IPF progression, but also given its potential enhancement of current standard of care therapies.  Orphan Drug Designation should significantly support our goal of progressing NXP002 through partnering and further development activities and, ultimately bringing solutions for fibrotic ILD indications to patients. We're thrilled that like us, the EMA has recognised the promise of this potential breakthrough medicine. We will now submit an application for US FDA orphan drug designation and continue discussions with potential future licensing partners and will provide further updates in due course as appropriate. "

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	+44 (0) 20 3003 8632
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

About IPF

IPF is a chronic lung disease characterised by progressive tissue scarring that prevents proper lung function. It is a progressive, fatal, age-associated lung disease affecting approximately three out of every one hundred thousand people in Europe. IPF typically presents in adults 65 or older and is usually fatal within two to five years after diagnosis.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDPKFBQCBKDOPB